Opus Genetics (IRD) Capital Expenditures Growth (1y) (2011 - 2019)
Opus Genetics (IRD) Capital Expenditures Growth (1y) (2011 - 2019) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | -27.93% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 227.76% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 0.57% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Opus Genetics | 263.72 Mn | 203.72 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2019 | 537.41% |
| Mar 31, 2019 | 423.06% |
| Sep 30, 2018 | 932.99% |
| Jun 30, 2018 | -93.02% |
| Mar 31, 2018 | -36.44% |
| Dec 31, 2017 | 13,249.63% |
| Sep 30, 2017 | 359.97% |
| Jun 30, 2017 | 378.39% |
| Mar 31, 2017 | -13.73% |
| Dec 31, 2016 | -95.89% |
| Sep 30, 2016 | -98.13% |
| Jun 30, 2016 | -34.54% |
| Mar 31, 2016 | -42.08% |
| Dec 31, 2015 | -11.64% |
| Sep 30, 2015 | 151.64% |
| Jun 30, 2015 | -57.36% |
| Mar 31, 2015 | 110.42% |
| Dec 31, 2014 | 200.68% |
| Sep 30, 2014 | -64.46% |
| Jun 30, 2014 | 944.30% |